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ABSTRACT 
Objective: To assess the individual’s predicted risk of developing a CVD event in 10 y using risk scores among persons with other 
disorders/diseases.  
Methods: This is a cross-sectional observational study conducted for a period of 6 mo among 283 subjects. Total risk was estimated individually by 
using Framingham Risk Scoring Algorithm and ASCVD risk estimator.  
Results: According to Framingham Risk score the prevalence of low risk (<10%) identified as 67.84% (192), followed by intermediate risk (10%-19%), 
19.08% (54), and high risk (≥20%) 13.07% (37). By using ASCVD Risk estimator, risk has reported in our study population was low risk (<5%) is 
48.76% (138), borderline risk (5-7.4%) is 13.07% (37), intermediate risk (7.5-19.9%) is about 25.09% (71), high risk (>20%) is about 13.07% (37). 
Conclusion: In this study burden of CVD risk was relatively low, which was estimated by both the Framingham scale and ASCVD Risk estimator. 
Risk scoring of individuals helps us to identify the patients at high risk of CV diseases and also helps in providing management strategies.  
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INTRODUCTION 
Cardiovascular diseases (CVD) brings up a group of diseases involving 
the heart and blood vessels and are the number one cause of death, 
accounting 30% of all deaths in the world. According to a joint report 
by the Harvard School of Public Health and World Economic Forum, 
CVD majorly contributes an economic burden leading to a staggering 
loss of $47 trillion globally over the period 2010-2030 [1]. 
A Century of research has shown that the occurrence of CVD relates 
to genetic, physiological, social and environmental factors. Hence, 
Prevention of CVD can be established by a coordinated set of actions, 
at public and individual level which aimed at eradicating, 
eliminating, or minimizing the impact of risk factors on CVDs and 
their related disability [2]. 
CVD risk factors are broadly classified into 2 groups: modifiable and non-
modifiable. The non-modifiable risk factors are those which one has no 
control over and include age and sex the modifiable risk factors are 
contrary and include; diabetes, hypertension, dyslipidemia, obesity, 
smoking, alcohol, diet, psychosocial factors and physical exercise. While 
significant advances in genetics and the ability to reduce social 
inequalities, has become evident that modification of these factors that 
cause atherosclerosis can also reduce mortality [3, 4].  
Risk estimation systems are developed to help the clinicians to 
assess the effects of risk factors that cause CVD and in planning of 
therapeutic strategies. Risk scoring makes patients aware of their 
risk status and can, therefore, serve as enough motivation for 
engaging in activities to lower overall risk. Many risk estimations 
systems are in existence where most of them include age, gender, 
smoking, serum lipids and hypertension as their core variables. 
CVD prevention remains as a challenge for the general population, 
politicians, and healthcare workers [2]. Assessment of an individual’s 
predicted Risk of developing a CVD event in 5 or 10 y has been identified 
as one of the ways to determine the burden of CVD risk and to guide 
treatment decisions [5]. Although there are many studies on CV risk 
prediction, the value of CV risk estimation is always justified because the 
prevalence of CV risk factors has continuously been changing in a region 
with different magnitude and direction over the past 30 y. While other 
factors like obesity, diabetes mellitus and cigarette smoking have 
become more prevalent. Furthermore, changes have not been similar 
between both the gender and among different ages [6].  
Hence this study aimed to assess total cardiovascular disease risk-
the probability of an individual experiencing a cardiovascular event 
over 10 y using the most recent Framingham Risk Scoring Algorithm 
and ASCVD risk estimator. 
MATERIALS AND METHODS 
This is a cross-sectional observational study which was conducted for a 
period of 6 mo in patients who are admitted as inpatients from 
November 2018and April 2019 in Dr. Pinnamaneni Siddhartha Institute 
of Medical Sciences and Research Foundation Andhra Pradesh (India). A 
total of 283 consecutive samples whose age is above 18 yold, agreed to 
participate voluntarily were recruited into the study and patients of 
above 65 y, Unresponsive and, or non-communicative, Patients whose 
records showed established or a history of any cardiovascular diseases 
are excluded. All the patients agreed to participate with a written 
consent form. Ethical clearance obtained from the Institutional Ethics 
Committee with a Protocol Approval No. UG/359/18. 
Data including the patient demographic details, medical and 
medication histories, diagnosis, treatment chart and data on 
laboratory investigations are collected from the patient medical 
records and risk was estimated individually by using Framingham 
Risk Scoring Algorithm and ASCVD risk estimator. 
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Fig. 1: Flowchart of study design 
 
Study tools 
a) Framingham risk score 
The globally best known and the most widely used tool for assessing 
the 10 y cardiovascular risk is the Framingham risk score. The 
Framingham group has pioneered many methods commonly used 
for estimation of risk. Several modified versions of the Framingham 
have also been developed and included in national, international 
guidelines, which are presented as either charts or tables [4]. 
Framingham risk is calculated by combining the variables gender, 
age, LDL cholesterol value, HDL cholesterol value, blood pressure, 
diabetes and smoking. The Framingham risk score was divided into 
three categories in this study to quantify the risk of developing CVD 
over the next 10 y. According to the criteria proposed by the 
Ministry of Health, the risk was categorized into low risk<10%, 
intermediaterisk10-19%andhighrisk≥20%accordingtocalculator. 
b) ASCVD risk estimator 
The ASCVD Risk scale (created by the American College of 
Cardiology) uses the variables: gender, age, race, whether a smoker 
or not, diabetic or not, treatment for high blood pressure or not, total 
cholesterol value and HDL, and systolic blood pressure, to calculate 
the risk of developing heart disease.  
The calculation of this score was made through the “ASCVD Risk 
Estimator” site. For risk classification, every patient’s data are 
entered in the ASCVD Risk Estimator. Patients with estimated 10-
year risk ≥ 20%, were considered at high risk, at intermediate risk if 
they had an estimated 10-year risk 7.5-19.9%, at borderline risk if 
they had an estimated 10-year risk 5-7.4%%, and at low risk if they 
had an estimated 10-year risk<5%, following the AHA/ACC criteria. 
Patients are considered as hypertensive and diabetic if using any 
medications and dyslipidemic if they showed LDL levels>160 mg/dl 
and/or HDL<40 mg/dl  
Statistical analyses 
The data was expressed by percentages. Data were analyzed using 
statistical tools like Epi-info 7.0 and Graph pad prism version 8.1. 
RESULTS 
Of all the patients admitted into the hospital during the study period, 
283 patients had met the inclusion criteria. Out of them 151 
(53.36%) were men and 132 (46.64%) were women, the Baseline 
characteristics of the study population are presented in table 1. The 
average age of the whole population was 47.4+10.9. Males were 
predominant. The age from 18 y above to 65 y was included in this 
study, which was divided into groups. 
The prevalence of Systolic BP according to standard guidelines in 
total sample Pre-Hypertension is about 37.10% (105), Stage-I is 
about 30.04% (85) and Stage-II is about 19.79% (56). The 
prevalence of Diastolic BP, Prehypertension, is about 32.51% (92), 
followed by stage-I 31.45% (89), Stage-II is 16.25% (46). The 
smoking history was ex-smoker 11.66% (33) followed by current 
smokers is 22.26% (63). In men (N1=151) is about ex-smoker 
21.19% (32), followed by Non-Smokers 38.41% (58), smokers 40 % 
(61). The prevalence of Smoking history in Women is about ex-
smoker 0.76%, followed by smokers 1.5%, Non-smokers is 
97.73%(129) and alcohol consumption history in women is about 
0.76%. In Men, the history of alcohol consumption is about ex-
alcoholic 11.26%, followed by Non-alcoholic 29.14%, Alcoholic 
59.60%.
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Table 1: Demographic details of the study population 
Age group Frequency Percent Men frequency Percent Women frequency Percent 
18-20 3 1.06% 2 1.32% 1 0.76% 
21-30 21 7.42% 14 9.27% 7 5.30% 
31-40 53 18.73% 33 21.85% 20 15.15% 
41-50 93 32.86% 42 27.81% 51 38.64% 
51-60 96 33.92% 49 32.45% 47 35.61% 
61-65 17 6.01% 11 7.28% 6 4.55% 
TOTAL N=283 100.00% N1=151 100.00% N2=132 100.00% 
Systolic BP MmHg Frequency Percent Frequency Percent Frequency Percent 
Normal (<120) 37 13.07% 17 11.26% 20 15.15% 
Pre-Hypertension (120-139) 105 37.10% 66 43.71% 39 29.55% 
Stage-1 (140-159) 85 30.04% 38 25.17% 47 35.61% 
Stage-2 (≥160) 56 19.79% 30 19.87% 26 19.70% 
Diastolic BP MmHg Frequency Percent Frequency Percent Frequency Percent 
Normal (<80) 56 19.79% 29 19.21% 27 20.45% 
Pre hypertension (80-89) 92 32.51% 48 31.79% 44 33.33% 
Stage-1 (90-99) 89 31.45% 47 31.13% 42 31.82% 
Stage-2 (≥100) 46 16.25% 27 17.88% 19 14.39% 
Smoker Frequency Percent Men frequency Percent Women frequency Percent 
Ex-smoker 33 11.66% 32 21.19% 1 0.76% 
No 187 66.08% 58 38.41% 129 97.73% 
Yes 63 22.26% 61 40.40% 2 1.52% 
Alcoholic Frequency Percent Men frequency Percent Women frequency Percent 
Ex-Alcoholic 17 6.01% 17 11.26% 0 0% 
No 175 61.84% 44 29.14% 131 99.24% 
Yes 91 32.16% 90 59.60% 1 0.76% 
Total cholesterol (mg/dl) Frequency Percent Men frequency Percent Women frequency Percent 
Desirable (<200 mg/dl) 227 80.21% 126 83.44% 101 76.52% 
Borderline high (200-239 mg/dl) 29 10.25% 15 9.93% 14 10.61% 
High (≥240 mg/dl) 27 9.54% 10 6.62% 17 12.88% 
HDL cholesterol (mg/dl) Frequency Percent Men frequency Percent Women frequency Percent 
Low (<40 mg/dl) 217 76.68% 121 80.13% 96 72.73% 
Normal (40-60 mg/dl) 66 23.32% 30 19.87% 36 27.27% 
LDL cholesterol (mg/dl) Frequency Percent Men frequency Percent Women frequency Percent 
Optimal (<100 mg/dl) 177 62.54% 101 66.89% 76 57.58% 
Near or Above Optimal (100- 
129 mg/dl) 
58 20.49% 30 19.87% 28 21.21% 
Borderline high (130-159 mg/dl) 28 9.89% 12 7.95% 16 12.12% 
High (160- 189 mg/dl) 10 3.53% 5 3.31% 5 3.79% 
Very high (≥190 mg/dl) 10 3.53% 3 1.99% 7 5.30% 
Diabetic? Frequency Percent Men frequency Percent Women frequency Percent 
Yes 128 45.23% 63 41.72% 65 49.24% 
No 155 54.77% 88 58.28% 67 50.76% 
Blood pressure 
being treated with medicines 
Frequency Percent Frequency Percent Frequency Percent 
Yes 138 48.76% 64 42.38% 73 55.30% 
No 145 51.24% 87 57.62% 59 44.70% 
 
The Lipid profile (total cholesterol, HDL, LDL) of the sample was 
mentioned in table 2. The total cholesterol levels were classified 
by ATP III classification. The prevalence of cholesterol levels in 
the whole sample is about desirable is 80.21% (227), followed 
by borderline high is 10.25% (29). HDL Cholesterol levels were 
classified into 3 categories; the prevalence of HDL in total 
sample is low is about 76.68% (217) and the standard value is 
approximately 23.32% (66). LDL Cholesterol levels are classified 
into 5; the prevalence of LDL cholesterol in total sample is 
optimal; about 62.54% (177), near or above optimal, is 20.49% 
(58). 
The prevalence of Diabetic mellitus in our study population is 128 
(45.23%); out of that 63 were males and 65 were females. Patients 
who are on anti-hypertensive therapy are about 48.76% (138) was 
male 64 out of 151 and females are about 73 out of 132. 
 
Table 2: Lipid profile of the study population 
Total cholesterol (mg/dl) Frequency Percent Men frequency Percent Women frequency Percent 
Desirable (<200 mg/dl) 227 80.21% 126 83.44% 101 76.52% 
Borderline high (200-239 mg/dl) 29 10.25% 15 9.93% 14 10.61% 
High (≥240 mg/dl) 27 9.54% 10 6.62% 17 12.88% 
Total N=283 100.00% N1= 151 100.00% N2=132 100.00% 
HDL cholesterol (mg/dl) Frequency Percent Men frequency Percent Women frequency Percent 
Low (<40 mg/dl) 217 76.68% 121 80.13% 96 72.73% 
Normal (40-60 mg/dl) 66 23.32% 30 19.87% 36 27.27% 
TOTAL N=283 100.00% N1=151 100.00% N2=132 100.00% 
LDL cholesterol (mg/dl) Frequency Percent Men frequency Percent Women frequency Percent 
Optimal (<100 mg/dl) 177 62.54% 101 66.89% 76 57.58% 
Near or Above Optimal (100-129 
mg/dl) 
58 20.49% 30 19.87% 28 21.21% 
Borderline High (130-159 mg/dl) 28 9.89% 12 7.95% 16 12.12% 
High (160-189 mg/dl) 10 3.53% 5 3.31% 5 3.79% 
Very high (≥190 mg/dl) 10 3.53% 3 1.99% 7 5.30% 
Total N=283 100.00% N1=151 100.00% N2=132 100.00% 
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Framingham risk 
According to Framingham scale the risk scores were categorized into 
low risk Intermediate risk, High risk. The prevalence of low risk 
identified is about 67.84% (192), followed by intermediate risk is 
about 19.08% (54), and high risk is about 13.07% (37) table 3.  
The prevalence of low risk identified in men is about 45.03%, 
followed by intermediate risk is about 31.13%, and high risk is about 
23.84%. The prevalence of low risk identified in women is about 
93.94%, followed by intermediate risk is about 5.30%, and high risk 
is about 0.76%. 
Stain and aspirin therapy 
According ASCVD Risk estimator, aspirin and statin therapy should 
also considered. In our study, Patients who are on Statin therapy are 
about 25.80% (73) in which 44 were male (25.80%) and 29 are 
female (29.14%). Aspirin therapy is about 70 (24.73%) in which 45 
were male is (29.80%) and 25 were females (18.94%). 
ASCVD risk 
The prevalence of Prior, current 10 y risk percent has identified by 
using ASCVD risk estimator and ASCVD score was classified into low 
risk(<5%), Borderline risk (5-7.4%), Intermediate risk (7.5-19.9%), 
High Risk(>20%). The prevalence of risk reported in our study 
population was low risk 48.76% (138), borderline risk 13.07% (37), 
intermediate-risk 25.09% (71), high Risk is about 13.07% (37) table 4 
According to ASCVD Risk estimation in our study, the majority of 
males have reported with low risk 36.42% (55), followed by 
Borderline risk in 10.60% (16), Intermediate risk 31.79% (48) and 
High Risk in 21.19%(32). In Female it was identified as low risk 
62.88% (83), Borderline risk 15.91% (21), and Intermediate risk 
17.42% (23) High Risk 3.79% (5). 
  
Table 3: Risk estimation using Framingham risk estimator 





Low Risk (<10%) 192 67.84% 68 45.03% 124 93.94% 
Intermediate risk (10%-19%) 54 19.08% 47 31.13% 7 5.30% 
High Risk (≥20%) 37 13.07% 36 23.84% 1 0.76% 
Total N=283 100.00% N1=151 100.00% N2=132 100.00% 
 
Table 4: Risk estimation using ASCVD risk estimator 
Ascvd categorized risk Frequency Percent Men frequency Percent Men frequency Percent 
Low Risk (<5%) 138 48.76% 55 36.42% 83 62.88% 
Borderline Risk (5%-7.4%) 37 13.07% 16 10.60% 21 15.91% 
Intermediate Risk (7.5-19.9%) 71 25.09% 48 31.79% 23 17.42% 
High Risk (≥20%) 37 13.07% 32 21.19% 5 3.79% 
Total 283 100.00% 151 100.00% 132 100.00% 
 
DISCUSSION 
Deaths from cardiovascular diseases (CVDs) in the world correspond 
to about 17.5 million people per year [7]. By 2030, cardiovascular 
disease (CVD) will account for 32.5% of all deaths; with coronary 
heart disease estimated to be the primary cause of death in 14.9% of 
males and 13.1% in females [8].  
In our study the variables included estimating risk score and 
percentage are age, sex, smoking status, alcohol, diabetes status, 
lipid profile, and blood pressure values consistent with the study 
conducted by Radha Valaulikar et al., which stated that age more 
than 60 y, smoking status and hypertension, were 
significantlyassociatedwitha10-yearcardiovascularriskof≥20%. 
These variables are routinely available in patients receiving medical 
care, particularly in primary care unit as screening for hypertension, 
dyslipidemia, smoking status, and fasting hyperglycemia as a part of 
normal preventive health measures. 
It was observed that in the studied male population, the frequency of 
hypertension was 39.56%, which is higher than the national average and 
that of other studies assessing cardiovascular risk [9, 10]. .Our research 
shows that low risk of CVD-related outcome was higher 45.03% by FRS 
and 48.76%, by ASCVD risk estimator similar to the study conducted by 
A G Ghorpade et al. As, both these studies were conducted in rural areas 
furthermore studies are needed to confirm this result.  
In this study, the prevalence of low risk identified in men and 
women is 45.03%, 36.42% and 93.94%, 62.88 respectively by this 
we can anticipate that women will suffer less than men from CVD 
over the next 10 y contrast to the study conducted by Nakhaie 
Mahmood Reza et al. where 10-year CVD risk was significantly 
higher among female than male. The other reasons of the low risk 
may be due to the lower prevalence of other significant risk factors 
like alcohol, smoking, diabetes and hypertension in female when 
compared to male. Also, the majority of the subjects, both male and 
female, showed desirable and optimal levels of lipid profile explains 
that most of them follow an active lifestyle and are at low risk as a 
sedentary lifestyle is one of the significant risk factors of CVD [11]. 
In our study, both the risk estimator scores have shown almost the 
same results that the majority are at low risk. When comparing the 
two scales, we found that the two cover the most significant risk 
factors; however, ASCVD Risk has more restrictions due to the cutoff 
values for its variables (age and cholesterol value). Thus it excludes 
a considerable portion of the sample, which does not occur on the 
Framingham scale, in which it was possible to calculate the Risk of 
CVD development, especially for those with high blood pressure at 
the time of data collection. So the Framingham scale has better 
results to assess cardiac risk over 18 y old, and is most suitable in 
population studies.  
Regardless of the scale chosen for the analysis of risk factors, an 
individual patient's awareness is essential for changing the habits 
that may bring harm to their health. Thus, monitoring of the patient 
by health professionals is of great importance, since as well as 
reducing the risk of CVDs, it can collaborate in the reception and 
integration of population into the health services. 
CONCLUSION 
In this study burden of CVD risk was relatively low, which was 
estimated by both Framingham scale and ASCVD Risk estimator. In 
spite the scale used, the frequent risk scoring of an individual helps 
us to identify the patients at high risk of Cardiovascular disorders 
and also helps in providing a rational means for taking decisions on 
intervening in a targeted way, thereby making best use of resources 
available to reduce cardiovascular risk. 
LIMITATIONS 
The primary limitation of our study is that the risk scores used are 
primarily intended for identifying high-risk population free of 
cardiovascular disease, not for patients who already have developed 
a hard CV event. As this is a cross-sectional study, we cannot 
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perform any causal correlations, thus conducting further studies 
with more populations for identification of cardiovascular events is 
necessary. 
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